We tested the possibility that simvastatin, a competitive inhibitor of HMG-CoA reductase related to mevinolin, might alter cholesterol saturation of gallbladder bile. Ten patients with Type IIa or IIb hypercholesterolemia underwent bile sampling before, and again after, treatment with 20 or 40 mg pe
Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin
β Scribed by GMB Berger; AD Marais; HC Seftel; SG Baker; D Mendelsohn; NH Welsh; BI Joffe
- Publisher
- Springer US
- Year
- 1989
- Tongue
- English
- Weight
- 767 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0920-3206
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract A new synthetic method for the preparation of pitavastatin is described. The approach circumvents various synthetic problems associated with the buildup of the 3,5βdihydroxyβC~7~ acid side chain of HMGβCoA reductase inhibitors (statins). The use of the C~6~βamide derivative **5** instea
On p. 1074, in Scheme 3, the correct formula of NK-104 should be as follows: 2) On p. 1077, line 16 should read as follows: (390 ml) was cooled to Γ 788, and 1.6m BuLi in hexane (374.4 g, 881 mmol) was added under 3) On p. 1078, line 15 should read as follows: As HPLC revealed the presence of mor
## Abstract For Abstract see ChemInform Abstract in Full Text.
The efficacy and safety of the HMG-CoA-reductase inhibitor pravastatin was assessed in a double-blind, placebo controlled study. Thirty patients (51 y) with hyperlipoproteinaemia Type IIa (N = 22) or IIb (N = 8) received for 16 weeks either pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. fo